Home  |  Contact

UniProtKB/Swiss-Prot Q9H6L2: Variant p.Asp209Asn

Transmembrane protein 231
Gene: TMEM231
Chromosomal location: 16q22.3
Variant information

Variant position:  209
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Aspartate (D) to Asparagine (N) at position 209 (D209N, p.Asp209Asn).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (D) to medium size and polar (N)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Joubert syndrome 20 (JBTS20) [MIM:614970]: A disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy and renal disease. {ECO:0000269|PubMed:23012439, ECO:0000269|PubMed:26477546}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In JBTS20.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  209
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  316
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.








Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 316 Transmembrane protein 231
Glycosylation 194 – 194 N-linked (GlcNAc...) asparagine
Glycosylation 199 – 199 N-linked (GlcNAc...) asparagine
Glycosylation 221 – 221 N-linked (GlcNAc...) asparagine

Literature citations

Mutations in TMEM231 cause Joubert syndrome in French Canadians.
Srour M.; Hamdan F.F.; Schwartzentruber J.A.; Patry L.; Ospina L.H.; Shevell M.I.; Desilets V.; Dobrzeniecka S.; Mathonnet G.; Lemyre E.; Massicotte C.; Labuda D.; Amrom D.; Andermann E.; Sebire G.; Maranda B.; Consortium F.C.; Rouleau G.A.; Majewski J.; Michaud J.L.;
J. Med. Genet. 49:636-641(2012)
Cited for: VARIANT JBTS20 ASN-209;

Joubert Syndrome in French Canadians and Identification of Mutations in CEP104.
Srour M.; Hamdan F.F.; McKnight D.; Davis E.; Mandel H.; Schwartzentruber J.; Martin B.; Patry L.; Nassif C.; Dionne-Laporte A.; Ospina L.H.; Lemyre E.; Massicotte C.; Laframboise R.; Maranda B.; Labuda D.; Decarie J.C.; Rypens F.; Goldsher D.; Fallet-Bianco C.; Soucy J.F.; Laberge A.M.; Maftei C.; Boycott K.; Brais B.; Boucher R.M.; Rouleau G.A.; Katsanis N.; Majewski J.; Elpeleg O.; Kukolich M.K.; Shalev S.; Michaud J.L.;
Am. J. Hum. Genet. 97:744-753(2015)
Cited for: VARIANT JBTS20 ASN-209;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.